Zolasta 4mg Injection contains zoledronic acid, a potent bisphosphonate indicated for the treatment and prevention of various bone-related conditions. Zoledronic acid acts by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. It is commonly prescribed for patients with osteoporosis, Paget’s disease of bone, and hypercalcemia of malignancy. Additionally, Zolasta is utilized in managing bone metastases associated with solid tumors to prevent skeletal-related events such as pathological fractures and spinal cord compression. The 4mg dose is administered intravenously, typically as a single infusion over no less than 15 minutes, with dosing frequency dependent on the specific indication and patient clinical status. Prior to administration, renal function should be assessed, as zoledronic acid is contraindicated in patients with severe renal impairment. Adequate hydration is recommended to minimize renal toxicity. Common adverse effects include transient flu-like symptoms, hypocalcemia, and potential renal dysfunction. Patients should receive supplemental calcium and vitamin D to mitigate hypocalcemia risk. Zolasta 4mg Injection should be used under strict medical supervision with appropriate monitoring of renal function, serum calcium, and overall patient response to therapy.